Search

Your search keyword '"Charles Gill"' showing total 28 results

Search Constraints

Start Over You searched for: Author "Charles Gill" Remove constraint Author: "Charles Gill" Topic pharmacology Remove constraint Topic: pharmacology
28 results on '"Charles Gill"'

Search Results

1. Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor

2. In Vitro and In Vivo Characterization of the Novel Oxabicyclooctane-Linked Bacterial Topoisomerase Inhibitor AM-8722, a Selective, Potent Inhibitor of Bacterial DNA Gyrase

Catalog

Books, media, physical & digital resources

3. Use of Translational Pharmacokinetic/Pharmacodynamic Infection Models To Understand the Impact of Neutropenia on the Efficacy of Tedizolid Phosphate

4. Isolation, structure elucidation and antibacterial activity of a new tetramic acid, ascosetin

5. Dual-Targeting Small-Molecule Inhibitors of the Staphylococcus aureus FMN Riboswitch Disrupt Riboflavin Homeostasis in an Infectious Setting

6. The Renal Outer Medullary Potassium Channel Inhibitor, MK-7145, Lowers Blood Pressure, and Manifests Features of Bartter's Syndrome Type II Phenotype

7. Efficacy of Caspofungin in a Juvenile Mouse Model of Central Nervous System Candidiasis

8. Coelomycin, a highly substituted 2,6-dioxo-pyrazine fungal metabolite antibacterial agent discovered by Staphylococcus aureus fitness test profiling

9. Antibacterial Evaluations of Thiazomycin

10. Efficacy of Caspofungin against Aspergillus flavus , Aspergillus terreus , and Aspergillus nidulans

11. Efficacy of the Echinocandin Caspofungin against Disseminated Aspergillosis and Candidiasis in Cyclophosphamide-Induced Immunosuppressed Mice

12. In Vivo Efficacy of a Novel Oxazolidinone Compound in Two Mouse Models of Infection

13. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)

14. Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates

15. In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373

16. Discovery of wall teichoic acid inhibitors as potential anti-MRSA β-lactam combination agents

17. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates

18. Real-time monitoring of bacterial infection in vivo: development of bioluminescent staphylococcal foreign-body and deep-thigh-wound mouse infection models

19. In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345)

20. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

21. New model of oropharyngeal and gastrointestinal colonization by Candida albicans in CD4+ T-cell-deficient mice for evaluation of antifungal agents

22. In vivo evaluation of three acid-stable azalide compounds, L-701,677, L-708,299 and L-708,365 compared to erythromycin, azithromycin and clarithromycin

23. Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

24. L-658,310, a new injectable cephalosporin. I. In vitro antibacterial properties

25. Elucidation of DnaE as the Antibacterial Target of the Natural Product, Nargenicin

26. PAP Inhibitor with In Vivo Efficacy Identified by Candida albicans Genetic Profiling of Natural Products

27. Comparative susceptibilities of Campylobacter pylori to norfloxacin and other agents

28. Comparative in vitro antimicrobial susceptibilities of a special panel of 74 Bacteroides fragilis group isolates in Wilkins-Chalgren agar with and without sheep blood